tbuckley/cabot-search huggingface dataset:
CYTOLOGY OF THE MYCOSIS FUNGOIDES AND THE SEZARY SYNDROME.
Authors: J. GOMEZ ORBANEJA, E. SANCHEZ YUS, L. DIAZ-FLORES, P. SIMON HUARTE
Journal: British Journal of Dermatology (1972)

Journal Article CYTOLOGY OF THE MYCOSIS FUNGOIDES AND THE SÉZARY SYNDROME: CORRELATION BETWEEN LIGHT AND ELECTRON MICROSCOPY Get access J. GOMEZ ORBANEJA, J. GOMEZ ORBANEJA Second Chair of Dermatology and Department of Electron Microscopy, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar E. SANCHEZ YUS, E. SANCHEZ YUS Second Chair of Dermatology and Department of Electron Microscopy, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar L. DIAZ‐FLORES, L. DIAZ‐FLORES Second Chair of Dermatology and Department of Electron Microscopy, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar P. SIMON HUARTE P. SIMON HUARTE Second Chair of Dermatology and Department of Electron Microscopy, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 87, Issue 2, 1 August 1972, Pages 96–105, https://doi.org/10.1111/j.1365-2133.1972.tb16182.x Published: 01 August 1972 Article history Accepted: 09 March 1972 Published: 01 August 1972
<i>De novo</i>acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study
Authors: Robert Paul Hasserjian, Federico Campigotto, Veronica Klepeis, Bin Fu, Sa A. Wang, Carlos Bueso-Ramos, Michael Joseph Cascio, Heesun Joyce Rogers, Eric Darryl Hsi, Craig Soderquist, Adam Bagg, Jiong Yan, Rachel Ochs, Attilio Orazi, Frank Moore, Amer Mahmoud, Tracy Irene George, Kathryn Foucar, Jamie Odem, Cassie Booth, William Morice, Daniel J. DeAngelo, David Steensma, Richard Maury Stone, Donna Neuberg, Daniel Alan Arber
Journal: American Journal of Hematology (2014)

It is controversial whether acute myeloid leukemia (AML) patients with 20-29% bone marrow (BM) blasts, formerly referred to as refractory anemia with excess blasts in transformation (RAEBT), should be considered AML or myelodysplastic syndrome (MDS) for the purposes of treatment and prognostication. We retrospectively studied 571 de novo AML in patients aged >50 years, including 142 RAEBT and 429 with ≥30% blasts (AML30), as well as 151 patients with 10-19% BM blasts (RAEB2). RAEBT patients were older and had lower white blood count, but higher hemoglobin, platelet count, and karyotype risk scores compared to AML30, while these features were similar to RAEB2. FLT3 and NPM1 mutations and monocytic morphology occurred more commonly in AML30 than in RAEBT. RAEBT patients were treated less often with induction therapy than AML30, whereas allogeneic stem cell transplant frequency was similar. The median and 4-year OS of RAEBT patients were longer than those of AML30 patients (20.5 vs 12.0 months and 28.6% vs 20.4%, respectively, P = 0.003); this difference in OS was manifested in patients in the intermediate UKMRC karyotype risk group, whereas OS of RAEBT patients and AML30 patients in the adverse karyotype risk group were not significantly different. Multivariable analysis showed that RAEBT (P < 0.0001), hemoglobin (P = 0.005), UKMRC karyotype risk group (P = 0.002), normal BM karyotype (P = 0.004), treatment with induction therapy (P < 0.0001), and stem cell transplant (P < 0.0001) were associated with longer OS. Our findings favor considering de novo RAEBT as a favorable prognostic subgroup of AML.
Treatment of Sarin Exposure
Authors: Joshua G Schier, Robert S Hoffman
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Biochemical characterization of GSK461364: A novel, potent, and selective inhibitor of Polo-like kinase-1 (Plk1)
Authors: Symon Erskine, Lenore Madden, Daniel Hassler, Gary Smith, Robert Copeland, Richard Gontarek
Journal: Cancer Research (2007)

3257  Polo-like kinases are evolutionarily conserved ser/thr kinases that play critical roles in regulating mitosis in diverse organisms from yeast to mammalian cells. In human cells, Polo-like kinase-1 (Plk1) has been implicated in a variety of different processes, including mitotic entry, spindle formation and cytokinesis. Overexpression of Plk1 is strongly associated with cancer and correlates with poor prognosis in some tumor types, and it is therefore a target of chemotherapeutic intervention. We have identified GSK461364 as a novel thiophene amide inhibitor of Plk1 which has excellent potency against a variety of tumor cell lines, is efficacious in PD models, and shows in vivo tumor inhibition in animal models. In order to interrogate the affinity and kinetics of this inhibitor, we developed and characterized a catalytic activity assay for full length Plk1 by formation of a complex with a polobox domain binding phospho-peptide. Under these assay conditions, GSK461364 was found to be a potent, ATP-competitive inhibitor of full length Plk1 enzyme with a Ki of 2.2 ± 0.6 nM. When evaluated against full-length Plk2 and Plk3, the inhibitor exhibited approximately 400-fold greater potency for Plk1. When tested against a panel of 48 additional kinases, it was at least 100-fold selective for Plk1. GSK461364 was also found to form a rapidly reversible complex with Plk1. Our data suggest that the excellent cellular activity and in vivo efficacy demonstrated by this compound is a result of the potent and selective inhibition of Plk1, and support the advancement of GSK461364 as a novel Plk1 inhibitor for the treatment of cancer.
THE ADRENAL CORTEX
Authors: ROBERT F. LOEB
Journal: JAMA (1935)

<h3>Note.</h3> —This article and the articles in the previous issues of The Journal are part of a series published under the auspices of the Council on Pharmacy and Chemistry. Other articles zvill appear in succeeding issues. When completed, the series will be published in book form.—Ed. It has been known for many years that destruction of the adrenal glands in the human being, or complete ablation of these structures in most animal species, results in death. Following the isolation and synthesis of epinephrine, it was shown that this secretion of the adrenal medulla would not maintain life. In human beings suffering from severe Addison's disease, as well as in totally adrenalectomized animals, this hormone, regardless of the dose or means of administration, proved to have little if any therapeutic effect. In experimental animals, extirpation of one adrenal and destruction of the medulla in the other led
Monitoring of influenza in the EISS European network member countries from October 2000 to April 2001
Authors: A Mosnier, W J Paget
Journal: Eurosurveillance (2001)

In countries covered by the European Influenza Surveillance Scheme (EISS), the 2000-2001 winter was marked mainly by the spread of influenza A(H1N1) viruses. Influenza B, which globally represented a minority of cases, was common later in the season and predominant in Great Britain, Ireland, and Portugal. Influenza activity was at its maximum during the period of January and February/March 2001 with little time lag between countries (maximum four weeks). Overall, the morbidity rates reported were much lower than for the previous season, illustrating a moderate level of influenza activity.
Tumor imaging metrics core: A centralized service for standardized tumor measurements at a multi-institutional collaborative cancer center
Authors: R. L. Zondervan, A. D. Van den Abbeele, M. A. Barish, T. Urban, G. R. Oliveira, M. Braschi, W. B. Hanlon, V. Frenkel, G. J. Harris
Journal: Journal of Clinical Oncology (2008)

20571 Background: Reliable tracking of lesion size and/or function over time is essential in clinical trials that use radiological measurements as surrogate endpoints. Current clinical practice typically does not provide the standardized measurements required for patients enrolled in clincal trials. It is difficult to maintain consistancy and reproducibility with the ad hoc methods used clinically to obtain tumor measurements. Additionally, these methods are also time-consuming for trial staff and radiologists. The Dana-Farber/Harvard Cancer Center established the Tumor Imaging Metrics Core (TIMC) in order to deliver standardized tumor measurement services to DF/HCC clinical trials in an efficient and cost-effective manner. Methods: The TIMC provides accurate analysis of CT, MRI and PET imaging studies for clinical trials. After the scans are analyzed by TIMC’s staff, the measurement results are then reviewed and finalized by Harvard faculty radiologists and nuclear medicine physicians. The results are stored in an SQL database and posted on TIMC’s secure website which is accessible to authorized trial staff and physicians. TIMC also provides protocol consultation to investigators planning clinical trials that require imaging as a primary or secondary surrogate endpoint. Results: Since TIMC’s beginning in 2004, over 2,500 scans have been reviewed with trial volume steadily increasing. Currently TIMC is managing tumor assessment in 146 oncology trials from 10 disease programs. An in-house study was done to determine inter-rater reliability between Image Analysts, with a reliability coefficient of 0.94. Clinical Trials’ staff have reported that TIMC’s service is fast, accurate, and generally improves reliability of tumor response measurement in clinical trials. Conclusions: TIMC addresses an outstanding need for efficient and consistent delivery of standardized radiologic measurements for clinical trials in a multi-institutional comprehensive cancer center. Its unique blend of expertise, efficient sharing of resources, advanced technology, and service, TIMC has become strategically indispensable to the Cancer Center and serves as a model for the future development of similar cores. No significant financial relationships to disclose.
Abstract 16662: GDF-15: Association With Pulmonary Hemodynamic Indices and Reduction With Serelaxin in Acute Heart Failure
Authors: Margaret F Prescott, Piotr Ponikowski, Veselin Mitrovic, Mikhail Ruda, Alberto Fernandez, Adriaan A Voors, Marco Metra, Gad Cotter, Yiming Zhang, Marion Dahlke
Journal: Circulation (2014)

Background: Growth differentiation factor 15 (GDF-15) appears to have a role in regulating inflammation and apoptosis and is up-regulated following injury to the liver, kidney, heart and lung. Elevated baseline (BL) levels of GDF-15 and increases over time have been shown to be associated with adverse events in heart failure (HF). GDF-15 was decreased following LVAD implantation and cardiac unloading in end stage HF. As previously reported, serelaxin improved Pulmonary Capillary Wedge Pressure (PCWP), mean Pulmonary Artery Pressure (mPAP), and Pulmonary Vascular Resistance (PVR) during a 20 h infusion period (all p&lt;0.005 vs. placebo [PBO]). A post-hoc analysis was performed to explore serelaxin effects on GDF-15 in acute HF (AHF) and whether GDF-15 is associated with pulmonary hemodynamics. Methods: Following serelaxin (30 ug/kg/d) or PBO infusion for 20 h in AHF patients, PCWP, mPAP, PVR, NTproBNP (Roche Diagnostics) and GDF-15 (pre-commercial kit, Roche Diagnostics) were measured in 32 serelaxin and 31 PBO treated patients. The effect of serelaxin on GDF-15 and NTproBNP was analyzed and the potential association of GDF-15 or NTproBNP with selected hemodynamic indices was explored combining treatment data from the two treatment arms. Results: Following the 20 h infusion period, serelaxin reduced GDF-15 vs BL (BL median 3192 pg/ml) by 16% (serelaxin vs PBO p=0.021) and reduced NTproBNP (BL median 3262 pg/ml) by 13% (serelaxin vs PBO p=0.021). GDF-15 at BL and 20 h was significantly associated with BL and 20 h NTproBNP (both p&lt;0.001), mPAP (both p&lt;0.025), and PVR (both p&lt;0.001). At 20 h GDF-15 and PCWP were significantly associated (p&lt;0.02) but their association at BL was not statistically significant (p=0.70). The association of NTproBNP at BL and 20 h was not statistically significant for BL or 20 h PCWP, mPAP or PVR (all p &gt;0.05). Conclusions: In this small invasive hemodynamic study in patients with AHF, serelaxin significantly reduced GDF-15 and NTproBNP and had favorable effects on pulmonary hemodynamics. GDF-15 levels at BL and 20 h showed a strong correlation with BL and 20 h values of mPAP and PVR. Additional studies measuring GDF-15 levels in acute HF patients with pulmonary congestion appear warranted.
Development of a sensitive sandwich-type ELISA for the quantification of the small heat-shock protein 27 (hsp27), a potential prognostic marker in hormone-regulated neoplasms, in tissue and cell extracts
Authors: Lothar Goretzki, Mo Saedi
Journal: Cancer Research (2004)

1307  Heat shock proteins (hsps) play a central role in the regulation of intracellular homeostasis, and differential expression of individual hsps occurs in a broad range of neoplastic processes. Hsp27 is a 27 kDa member of the heat shock protein family which has previously been studied as p29, srp27, and p24. Increasing evidence supports a role for Hsp27 in cell growth and motility. High concentrations of Hsp27 have been associated with rapid proliferation in hormonally sensitive tissues, such as breast, endometrium, and prostate. Elevated levels of Hsp27 are associated with aggressive growth and cell invasion, which often result in poor prognosis in breast, ovarian, and prostate carcinomas. An immunoassay for the quantification of the biological marker Hsp27 was developed and evaluated for its use with extracts of breast cancer tissue and total cell lysates of various cell lines. The assay is based on a murine monoclonal capture antibody and a rabbit polyclonal detector antibody. Horseradish peroxidase-conjugated goat anti-rabbit antibody enabled measurement of the bound antigen. The detection limit of the Hsp27 assay is 0.75 m/ml, with a linear dose-response relationship up to 50 ng/ml. The sensitivity of the assay allowed the specific measurement and comparison of hsp27 concentrations in normal breast tissue vs. breast cancer tissue. The hsp27 level in normal breast tissue was 0.3 ng/μg cytosolic protein vs. 5.2 ng/μg cytosolic protein in breast cancer tissue. The assay was validated for detergent extracts using recovery tests.It is concluded that the above immunoassay is well suited for quantification of Hsp27 in extracts of tumor tissues and cultured cells and thus should help in deciphering the role of hsp27 in carcinogenesis of endocrine sensitive tumors.
The Lung: Scientific Foundations
Authors: Ronald G Crystal, John B. West
Journal: Annals of Internal Medicine (1991)

Section Titles I. General Biologic Processes II. Strategies for Understanding the Lung in Health and Disease III. Major Components IV. Integrated Morphology: Growth and Form V. Integrated Physiology and Pathophysiology VI. The Fetal, Perinatal, Postnatal, and Aging Lung VII. Lung Injury, Defense and Repair VIII. Special Environments and Interventions
Abstract 1433: Erythropoietin (Epo) Has Direct Cardioprotective Effects on Post-MI Hearts through Epo-Epo Receptor System in Cardiomyocytes
Authors: Yuriko Niitsuma, Hiroyuki Takano, Yingjie Qin, Kazutaka Ueda, Hiroshi Hasegawa, Masaru Miyazaki, Issei Komuro
Journal: Circulation (2006)
Abstract 17541: An Education Intervention Focused on Self-monitoring for Symptom and Sodium Intake Improves Adherence to the Low Sodium Diet and Health Outcome in Patients with Heart Failure
Authors: Eun Kyeung Song, Debra K Moser, Seok-Min Kang, Terry A Lennie
Journal: Circulation (2014)

Background: Despite the clinical emphasis on recommending a low sodium diet (LSD), adherence to a LSD remains poor in patients with heart failure (HF). Additional research is needed to determine successful interventions to improve adherence to a LSD and health outcomes. Purpose: To determine the effect of an education intervention on adherence to a LSD and health outcomes. Method: A total of 109 HF patients (age 64±9 years, 29% female) who were non-adherent to LSD, indicating &gt; 3g of 24-hour urinary sodium excretion (24hr UNa) at baseline, were randomly assigned to one of 3 groups: 1) symptom monitoring and restricted 3 gram sodium diet (SMART) group, 2) the telephone monitoring (TM) group, or 3) usual care control group. The SMART group received individualized teaching and guidance of self-monitoring for worsening symptom and sodium intake using symptom and food diary for 4 sessions over 8 weeks. Patients assigned to either of the 2 intervention groups (SMART or TM) received phone calls every 2 weeks over 8 weeks. At 6 months follow-up, adherence to a LSD was assessed using 24hr UNa. Patients were followed for 1 year to determine time to first event of hospitalization or death due to cardiac problems. Repeated measures ANOVA and Cox regression were used to determine the effect of intervention. Results: The SMART group (n=37) showed a significant reduction in sodium intake across time compared to the TM group (n=35) and control group (n=37) (p= .022). In the Cox regression, patients in the SMART group had longer cardiac event-free survival compared to the control group after controlling for age, gender, ejection fraction, angiotensin-converting enzyme inhibitor use, and better blocker use (p=.008). Conclusion: An education intervention focused on self-monitoring for symptom and sodium intake improved adherence to LSD and health outcomes in patients with HF. Helping patients engage in self-monitoring for symptom and sodium intake by themselves can promote better health outcome.
Varicella zoster virus retrobulbar optic neuritis preceding retinitis in patients with acquired immune deficiency syndrome
Authors: Michael S Lee, Elizabeth L Cooney, Kathleen M Stoessel, Ray F Gariano
Journal: Ophthalmology (1998)

This study aimed to describe a recently recognized and rare presentation of varicella zoster virus (VZV) retrobulbar optic neuritis preceding retinitis in patients with acquired immune deficiency syndrome and to identify factors that may relate to improved visual outcome.Diagnosis, treatment, and clinical course are described for three eyes of two patients with this viral infection.Patients had decreased vision, headache, and recent zoster dermatitis. Varicella zoster virus retrobulbar optic neuritis was diagnosed on the bases of clinical, laboratory, and electrophysiologic examination results. Profound vision loss and peripheral retinitis ensued despite intravenous antiviral treatment. Combination intravenous and intravitreous antiviral injections were administered with dramatic visual recovery.Varicella zoster virus retrobulbar optic neuritis should be considered in immunocompromised patients with visual loss. Early diagnosis and aggressive combination therapy via systemic and intravitreous routes may enable return of useful vision.
Supreme Court Rules Against Teaching HospitalsProject USA
Authors: R Smith
Journal: JAMA (1998)

Objective:To assess the effectiveness of the nonprescription combination of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain.Design:Three double-blind, randomized, parallel-group, single-dose, placebo-controlled studies.Setting:Private practice, referral centers, and general community.Patients:Migraineurs with moderate or severe headache pain who met International Headache Society diagnostic criteria for migraine with aura or without aura. The most severely disabled segment of migraineurs, including those whose attacks usually required bed rest, or who vomited 20% or more of the time, were excluded. Of the 1357 enrolled patients, 1250 took study medication and 1220 were included in the efficacy-evaluable data set.Intervention:Two tablets of the nonprescription combination of acetaminophen, aspirin, and caffeine or placebo taken orally as a single-dose treatment of 1 eligible acute migraine attack.Main Outcome Measures:Pain intensity difference from baseline; percentage of patients with pain reduced to mild or none.Results:Significantly greater reductions in migraine headache pain intensity 1 to 6 hours after dose were seen in patients taking the acetaminophen, aspirin, and caffeine combination than in those taking placebo in each of the 3 studies. Pain intensity was reduced to mild or none 2 hours after dose in 59.3% of the 602 drug-treated patients compared with 32.8% of the 618 placebo-treated patients (P&lt;.001; 95% confidence interval [CI], 55%-63% for drug, 29%-37% for placebo); at 6 hours after dose, 79% vs 52%, respectively, had pain reduced to mild or none (P&lt;.001; 95% CI, 75%-82% vs 48%-56%). In addition, by 6 hours after dose, 50.8% of the drug-treated patients were pain free compared with 23.5% of the placebo-treated patients (P&lt;.001; 95% CI, 47%-55% for drug, 20%-27% for placebo). Other migraine headache characteristics, such as nausea, photophobia, phonophobia, and functional disability, were significantly improved 2 to 6 hours after treatment with the acetaminophen, aspirin, and caffeine combination compared with placebo (P&lt;.01).Conclusions:The nonprescription combination of acetaminophen, aspirin, and caffeine was highly effective for the treatment of migraine headache pain as well as for alleviating the nausea, photophobia, phonophobia, and functional disability associated with migraine attacks. This drug combination also has an excellent safety profile and is well tolerated.